Luneau Technology group announced that it has acquired Padova, Italy-based Next Sight, maker of the Nexy retinal screening device.
Terms of the deal were not disclosed.
The acquisition brings to Luneau increased capabilities–covering both back and front of the eye. Luneau develops, manufactures, and markets devices aimed at ophthalmic, optometrists, and optical professionals with products on wavefront technology. Its brand Visionix offers refraction, diagnostic and screening instruments, including the recently launched Vx 120+Dry Eye and the Eye Refract.
Next Sight develops robotic and IT technologies to provide ophthalmic diagnostic solutions. Next Sight produces Nexy, a device which allows retina screening through a platform to securely send patient data to remote locations. Nexy combines robotic technology, telehealth platform, image management solutions and secured data transfer.
“It is a great opportunity for Luneau Technology to expand our offer. We are very excited to enter the telehealth space and welcome Paola Griggio among our management team to lead this new capability for the group,” Marc Abitbol, PhD, President and CEO Luneau Technology, said in a company news release.
Paola Griggio, PhD and MBA – CEO of Next Sight, will continue to manage future initiatives around retinal topics, but she will also take up a key leadership role as she is appointed VP Telehealth for Luneau Technology group.
The complementary activities among the two companies and their respective experience will allow the Luneau Technology group to meet even better the expectations of the visual health sector, according to Luneau.